Hypercholesterolaemia and its management

BMJ

Volumn 337, Issue 7668, 2008, Pages 503-508

  Bhatnagar, Deepak ^a,b   Soran, Handrean ^a   Durrington, Paul N ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL OLDHAM HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CHOLESTEROL; CYCLOSPORIN A; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MACROLIDE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; SIMVASTATIN; STATIN; TACROLIMUS; VERY LOW DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ATTRIBUTABLE RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MYOSITIS; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; DRUG COMBINATION; LIFESTYLE; PRACTICE GUIDELINE;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC;

EID: 51249095156     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a993     Document Type: Review

References (28)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
2. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-82.
3. Chaudhury M. Blood analytes. In: Sproston K, Primatesta P, eds. Health survey for England 2003. Risk factors for cardiovascular disease. Vol 2. London; Stationery Office, 2004:241-87.
4. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol 2008;93:27-42.
5. Stamler J, Wentworth D, Neaton JD. "Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?" Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT)." JAMA 1986;256:2823-8.
6. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990;81:1721-33.
7. Department of Health. National service framework for coronary heart disease. London: DoH, 2000.
8. Wood DA, Wray R, Poulter N, Williams B, Kirby M, Patel V, et al. JBS2: joint British guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl V):v1-52.
9. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001:2717-52.
10. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolaemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001:2863-913.
11. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinaemia. Circulation 1974;49:476-88.
12. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8.
13. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-8.
14. Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001:2835-62.
15. Durrington PN. Dyslipidaemia. Lancet 2003;362:717-31.
16. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolemia. BMJ 2000;321:1497-500.
17. Durrington PN, Prais H, Bhatnagar D, France M, Crowley V, Khan J, et al. Indications for cholesterol lowering medication: comparison of risk-assessment methods. Lancet 1999;353:278-81.
18. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
19. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: NICE, 2008.www.nice.org.uk/CG67
20. Rioufol G, Gilard M, Finet G, Ginon I, Boschat J, André-Fouet X. Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound. Circulation 2004;110:2875-80.
21. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HAW. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998;316:1213-9.
22. Katan MJ, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R, et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78:965-78.
23. Law MR, Wald NJ, Rudnicka AR. Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-30.
24. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
25. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al. Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medicine 2003;163:553-64.
26. Betteridge DJ, Illingworth DR, Shepherd J, eds. Lipoproteins in health and disease. London: Arnold, 1999.
27. Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001.
28. Durrington PN. Hyperlipidaemia diagnosis and management. London: Hodder Arnold, 2007.